Where Technology Aligns with Pharmaceutical Execution
Needle-free injection has been extensively explored across the pharmaceutical industry for decades, particularly in vaccines, biologics, and emergency therapeutics. While its clinical and patient-centric benefits are well recognized, broad commercialization has historically been constrained by development complexity, regulatory alignment, and integration with established pharmaceutical workflows.
Quinovare is positioned at this intersection — bridging validated needle-free delivery technology with practical, development-ready solutions designed to align with pharmaceutical manufacturing, regulatory, and lifecycle management requirements.
Why Needle-Free, for Pharma
Patient & User Value
Enabling broader adoption and long-term self-administration
• Reduces injection anxiety and needle-associated discomfort
• Improves patient acceptance and compliance, particularly in chronic use
• Supports safe and intuitive self-administration in non-clinical settings
Drug & Delivery Performance Value
Optimizing delivery performance across diverse drug types
• Rapid dispersion enables fast onset for acute and emergency therapies
• Controlled tissue distribution supports sustained-release formulations
• Micro-jet delivery enhances cellular uptake for nucleic acid-based drugs
Why Needle-Free, for Pharma
Product Differentiation & Lifecycle Value
• Enables differentiated delivery formats within competitive markets
• Supports line extensions and next-generation product strategies
• Adds lifecycle value without altering the core drug substance
Development, Regulatory & Commercialization Value
Minimizing development risk while enabling scalable deployment
• Compatible with standard fill-finish, cartridges, and vial formats
• No fundamental change to drug formulation or CMC pathway
• Supports combination product development and regulatory submissions
• Designed for transition from clinical development to commercial scale
Value Delivered Through Partnership
Clear, structured benefits aligned with pharmaceutical development, lifecycle management, and commercialization.
Product-Level Differentiation
• Enables needle-free variants without changing the core drug substance
• Creates defensible product formats beyond needle-based injectablee
• Supports differentiated SKUs and delivery-based product segmentation
Development & Cost Efficiency
• Potential dose optimization through improved delivery efficiency
• Reduces complexity compared to developing new formulations
• Leverages existing manufacturing and supply infrastructure
Portfolio & Lifecycle Expansion
• Extends product lifecycle through delivery-based line extensions
• Supports geographic and indication expansion strategies
• Provides an additional pathway for portfolio renewal beyond loss of exclusivity
Patient Adoption & Market Access
• Improves patient acceptance and long-term compliance
• Supports self-administration and out-of-clinic use
• Enables differentiated value propositions aligned with payer and access strategies
Partnership-Ready Assets
Established assets and capabilities designed to support pharmaceutical evaluation, development, and scale-up.
Patents & Technology Barriers
A globally protected IP portfolio covering jetting mechanisms, device architecture, and container compatibility—enabling defensible platform collaboration under clear licensing boundaries.
Data & Scientific Evidence
A growing body of safety and performance evidence, supported by peer-reviewed publications—structured as evaluation-ready packages to accelerate partner technical diligence and development planning.
Industrialization & Manufacturing Readiness
Industrialization-ready engineering and validated automation concepts, with scalable manufacturing capacity—supporting the transition from development builds to clinical and commercial supply.
Manufacturing & Supply Readiness
Manufacturing Capacity
Manufacturing capacity is configured on a program-specific basis, with validated production capability for needle-free injector systems and disposable components. Capacity can be expanded through dedicated line deployment and regional manufacturing strategies to support clinical and commercial demand.
Quality Systems & Compliance
Manufacturing operations are supported by an ISO 13485–compliant quality management system and controlled production environments. End-to-end traceability is maintained across materials, components, and finished devices to meet pharmaceutical and combination product requirements.
Platform-Agnostic Manufacturing Architecture
Manufacturing architecture is designed to be platform-agnostic and scalable, with production lines and assembly processes configured according to platform format, container type, and expected commercial volume. This approach supports both existing platforms and future prefilled-ready, single-use formats without disrupting pharmaceutical supply strategies.
Supply Philosophy
Manufacturing and supply are structured to support pharmaceutical partners from early clinical supply through global commercialization, with emphasis on reliability, regulatory compliance, and long-term continuity rather than short-term volume optimization.
How We Engage with Pharmaceutical Partners
A structured, stage-based collaboration pathway aligned with pharmaceutical development, regulatory, and commercialization requirements.
Together Toward Global Impact
We work with pharmaceutical partners to translate validated drug–device innovation into reliable, scalable, and globally deployable solutions. Our focus is not only on technology performance, but on execution—ensuring that needle-free delivery platforms can move efficiently from development into regulated markets and long-term clinical use.
For partners seeking differentiated delivery formats, lifecycle extension opportunities, or scalable alternatives to traditional injection systems, Quinovare provides a structured pathway from collaboration to commercialization.